Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Summary There is increasing interest to therapeutically exploit metabolic differences between normal and cancer cells. We show that kinase inhibitors (KIs) and biguanides synergistically and selectively target a variety of cancer cells. Synthesis of non-essential amino acids (NEAA) aspartate, asparagine and serine, as well as glutamine metabolism, are major determinants of the efficacy of KI/biguanide combinations. The mTORC1/4E-BP axis regulates aspartate, asparagine and serine synthesis by modulating mRNA translation, while ablation of 4E-BP1/2 substantially decreases sensitivity of breast cancer and melanoma cells to KI/biguanide combinations. Efficacy of the KI/biguanide combinations is also determined by HIF-1α-dependent perturbations in glutamine metabolism which were observed in VHL-deficient renal cancer cells. This suggests that cancer cells display metabolic plasticity by engaging non-redundant adaptive mechanisms which allows them to survive therapeutic insults that target cancer metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 4×
“PHGDHandPSAT1 are overexpressed in subtypes of breast cancer, melanoma, cervical cancer, and glioma (DeBerardinis and Chandel, 2016) and are linked to poor prognosis in lung cancers (DeNicola et al.”
BackgroundInfluentialReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
Birsoy, K., Wang, T., Chen, W. W., Freinkman, E., Abu-Remaileh, M., & Sabatini, D. M. (2015) · Cell · doi:10.1016/j.cell.2015.07.016 · Cited by 1,388
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335 · cited 2×
“HER2 upregulates HIF-1a, even under normoxic conditions (Semenza, 2013), which is required for neoplastic growth (Whelan et al.”
BackgroundReductive carboxylation supports growth in tumour cells with defective mitochondria
Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328 · cited 1×
“…is associated with induction of reductive glutamine metabolism that allows the synthesis of CAC intermediates for biosynthetic pathways, including lipogenesis, and is implicated in maintaining REDOX homeostasis when OXPHOS is inhibited (Gravel et al., 2014; Jiang et al., 2016; Mullen et al., 2011).”
BackgroundThe translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Apoptotic cell clearance: basic biology and therapeutic potential
Poon, I. K. H., Lucas, C. D., Rossi, A. G., & Ravichandran, K. S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3607 · Cited by 1,223 · cited 1×
“Of note, the absolute number of apoptotic cells in tumors was lower than in cell culture, consistent with efficient removal of apoptotic cells by phagocytes in vivo (Poon et al., 2014) and lower achievable concentration of phenformin in plasma ( 2 mM) and tissues ( 1 mM) (Table S1) versus cell culture ( 100–250 mM).”
BackgroundSupporting aspartate biosynthesis is an essential function of respiration in proliferating cells
Sullivan, L. B., Gui, D. Y., Hosios, A. M., Bush, L. N., Freinkman, E., & Vander Heiden, M. G. (2015) · Cell · doi:10.1016/j.cell.2015.07.017 · Cited by 1,173
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis
Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., Heffron, G., Metallo, C. M., Muranen, T., Sharfi, H., et al. (2011) · Nature Genetics · doi:10.1038/ng.890 · Cited by 1,120
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
Wheaton, W. W., Weinberg, S. E., Hamanaka, R. B., Soberanes, S., Sullivan, L. B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G. M., Budigner, G. S., et al. (2014) · eLife · doi:10.7554/elife.02242 · Cited by 1,105 · cited 2×
“Metfor-min (an anti-diabetic biguanide) induces energy stress via complex I inhibition and oxidative phosphorylation (OXPHOS) reduction (Andrzejewski et al., 2014; Bridges et al., 2014; Wheaton et al., 2014), which leads to a compensatory increase in glycolysis (Javeshghani et al., 2012).”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Self-citationRegulation of mammalian nucleotide metabolism and biosynthesis
Lane, A. N., & Fan, T. W.-M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv047 · Cited by 959
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Self-citationAn inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928 · cited 2×
“One reason for this may relate to sub-optimal pharmacokinetics of metformin (Chandel et al., 2016; Dowling et al., 2016), an issue that may be addressed by the use of novel biguanides or other OXPHOS inhibitors (Molina et al., 2018; Zhang et al., 2016).”
BackgroundMetformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Morita, M., Gravel, S.-P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.001 · Cited by 842 · cited 6×
“…Loss Decreases the Efficacy of the KI/Biguanide Combinations 4E-BP1/2 status in the cells determines translation of mRNAs encoding proteins that play critical roles in aspartate, asparagine, and serine synthesis (Figure 5B) and mitochondrial functions (Gandin et al., 2016b; Morita et al., 2013).”
BackgroundMethodInfluentialSelf-citationTargeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 6×
“This is in part mediated by the effects of mTORC1 on 4E-BPs and, consequently, on the eIF4F complex assembly (Bhat et al., 2015).”
BackgroundMethodInfluentialSelf-citationEnvironment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer
Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O’Brien, J. P., Pierce, K. A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.007 · Cited by 737
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661 · cited 2×
“Metformin (an anti-diabetic biguanide) induces energy stress via complex I inhibition and oxidative phosphorylation (OXPHOS) reduction (Andrzejewski et al., 2014; Bridges et al., 2014; Wheaton et al., 2014), which leads to a compensatory increase in glycolysis (Javeshghani et al.”
BackgroundSelf-citationMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Reductive carboxylation supports redox homeostasis during anchorage-independent growth
Jiang, L., Shestov, A. A., Swain, P., Yang, C., Parker, S. J., Wang, Q. A., Terada, L. S., Adams, N. D., McCabe, M. T., Pietrak, B., et al. (2016) · Nature · doi:10.1038/nature17393 · Cited by 582 · cited 1×
“Phenformin also increased a-KG/citrate ratio (Figure 2D), which is associated with induction of reductive glutamine metabolism that allows the synthesis of CAC intermediates for biosynthetic pathways, including lipogenesis, and is implicated in maintaining REDOX homeostasis when OXPHOS is inhibited (Gravel et al., 201…”
BackgroundmTOR coordinates protein synthesis, mitochondrial activity and proliferation
Morita, M., Gravel, S.-P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., & Topisirovic, I. (2015) · Cell Cycle · doi:10.4161/15384101.2014.991572 · Cited by 552
Self-citationAsparagine promotes cancer cell proliferation through use as an amino acid exchange factor
Krall, A. S., Xu, S., Graeber, T. G., Braas, D., & Christofk, H. R. (2016) · Nature Communications · doi:10.1038/ncomms11457 · Cited by 504
Pyruvate carboxylase is critical for non–small-cell lung cancer proliferation
Sellers, K., Fox, M. P., Bousamra, M., Slone, S. P., Higashi, R. M., Miller, D. M., Wang, Y., Yan, J., Yuneva, M. O., Deshpande, R., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci72873 · Cited by 497 · cited 1×
“Elevated PC expression and/or activity is observed in breast cancer and non-small-cell lung cancer (Phannasil et al., 2017; Sellers et al., 2015).”
BackgroundAsparagine Plays a Critical Role in Regulating Cellular Adaptation to Glutamine Depletion
Zhang, J., Fan, J., Venneti, S., Cross, J. R., Takagi, T., Bhinder, B., Djaballah, H., Kanai, M., Cheng, E. H., Judkins, A. R., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.018 · Cited by 439 · cited 1×
“ASNS is also required for KRAS-driven oncogenesis (Gwinn et al., 2018); glioma, neuroblastoma, and mouse sarcoma growth (Hettmer et al., 2015; Zhang et al., 2014); and breast cancer metastasis (Knott et al., 2018).”
BackgroundThe Hydroxylase Inhibitor Dimethyloxalylglycine Is Protective in a Murine Model of Colitis
Cummins, E. P., Seeballuck, F., Keely, S. J., Mangan, N. E., Callanan, J. J., Fallon, P. G., & Taylor, C. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.012 · Cited by 407 · cited 6×
“Indeed, stabilization of HIF-1a with dimethyloxallyl glycine (DMOG) (Cummins et al., 2008) decreased sensitivity of the RCC4-VHL cells to the drug combination (Figures S7B and S7C).”
BackgroundInfluentialAnisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Sun, R. C., & Denko, N. C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.022 · Cited by 344 · cited 7×
“Moreover, the phenformin/lapatinib combination decreased OGDH levels in VHL-proficient, but not -defi- cient, cells (Figure S7J), which is consistent with the drugs acting via HIF-1 a .”
BackgroundInfluentialGameiro, P. A., Yang, J., Metelo, A. M., Pérez-Carro, R., Baker, R., Wang, Z., Arreola, A., Rathmell, W. K., Olumi, A., López-Larrubia, P., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.002 · Cited by 325 · cited 1×
“Loss of VHL triggers reductive glutamine metabolism (Gameiro et al., 2013), which was confirmed by 13 C 5 -glutamine tracing that revealed higher levels of citrate (m+5), malate (m+3), and aspartate (m+3) isotopomers in RCC4-mock versus RCC4-VHL cells (Figures 7C and S7E).”
BackgroundRegulation of mammalian acetyl-CoA carboxylase
Munday, M. R. (2002) · Biochemical Society Transactions · doi:10.1042/bst0301059 · Cited by 301 · cited 4×
“The following primary antibodies were used: anti-b -actin (Clone AC-15) #A1978, anti-HA #H6908, anti-PHGDH #HPA021241, from Sigma (Saint Louis, Missouri, USA); anti-4E-BP1(53H11) #9644, anti-p-4E-BP1 (Ser65) (174A9) #9456, anti-4E-BP2 #2845, anti-p-rpS6 (Ser240/244) #2215, anti-S6K #2708, anti p-S6K (Thr389) (#9234),…”
BackgroundInfluentialMetabolic plasticity underpins innate and acquired resistance to LDHA inhibition
Boudreau, A., Purkey, H. E., Hitz, A., Robarge, K., Peterson, D., Labadie, S., Kwong, M., Hong, R., Gao, M., Del Nagro, C., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2143 · Cited by 280
Enzymes of serine metabolism in normal, developing and neoplastic rat tissues
Snell, K. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90021-9 · Cited by 267 · cited 1×
“Cancer cells exhibit increased serine biosynthesis (Snell, 1984).”
Gwinn, D. M., Lee, A. G., Briones-Martin-del-Campo, M., Conn, C. S., Simpson, D. R., Scott, A. I., Le, A., Cowan, T. M., Ruggero, D., & Sweet-Cordero, E. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.003 · Cited by 230 · cited 1×
“ASNS is also required for KRAS-driven oncogenesis (Gwinn et al., 2018); glioma, neuroblastoma, and mouse sarcoma growth (Hettmer et al.”
BackgroundZhao, F., Mancuso, A., Bui, T. V., Tong, X., Gruber, J. J., Swider, C. R., Sanchez, P. V., Lum, J. J., Sayed, N., Melo, J. V., et al. (2010) · Oncogene · doi:10.1038/onc.2010.67 · Cited by 179
PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis
Zhang, B., Zheng, A., Hydbring, P., Ambroise, G., Ouchida, A. T., Goiny, M., Vakifahmetoglu-Norberg, H., & Norberg, E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.067 · Cited by 178
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant
Chandel, N. S., Avizonis, D., Reczek, C. R., Weinberg, S. E., Menz, S., Neuhaus, R., Christian, S., Haegebarth, A., Algire, C., & Pollak, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.010 · Cited by 176 · cited 5×
“This is explained by serine being a centralnodefor the biosynthesisofmanymetabolites (e.g.,nucleotides, folate metabolism), amino acid transport, and redox homeostasis (DeBerardinis and Chandel, 2016).”
BackgroundInfluentialSerine deprivation enhances antineoplastic activity of biguanides
Gravel, S.-P., Hulea, L., Toban, N., Birman, E., Blouin, M.-J., Zakikhani, M., Zhao, Y., Topisirovic, I., St-Pierre, J., & Pollak, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2643-t · Cited by 138 · cited 5×
“Measurement of glucose concentration in samples was done as previously described (Gravel et al., 2014).”
BackgroundMethodInfluentialSelf-citationZhang, J., Cao, J., Weng, Q., Wu, R., Yan, Y., Jing, H., Zhu, H., He, Q., & Yang, B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013910 · Cited by 56
L-Asparaginase Therapy for Leukemia and Other Malignant Neoplasms: Remission in Human Leukemia
Hill, J. M. (1967) · JAMA · doi:10.1001/jama.1967.03130220070012 · Cited by 1
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“For example, in the view of metabolic plasticity [225, 226] , therapies that target metabolism-modulating pathways would presumably be required to aim at parallel mechanisms accomplishing bio-energetic essentials, or to couple metabolic inhibitors with therapeutic interventions which conquer plasticity of cancer cells…”
BackgroundmTOR as a central regulator of lifespan and aging
Papadopoli, D., Boulay, K., Kazak, L., Pollak, M., Mallette, F., Topisirovic, I., & Hulea, L. (2019) · F1000Research · doi:10.12688/f1000research.17196.1 · Cited by 440
Self-citationShiratori, R., Furuichi, K., Yamaguchi, M., Miyazaki, N., Aoki, H., Chibana, H., Ito, K., & Aoki, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-55296-3 · Cited by 291
Kondo, H., Ratcliffe, C. D. H., Hooper, S., Ellis, J., MacRae, J. I., Hennequart, M., Dunsby, C. W., Anderson, K. I., & Sahai, E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108750 · Cited by 109
“Heterogeneity at this level and switching between metabolic states present a challenge to targeted therapies, including those targeting metabolic regulation directly and those targeting upstream signaling that controls metabolic programs (Hulea et al., 2018).”
BackgroundFibroblasts as Modulators of Local and Systemic Cancer Metabolism
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019) · Cancers · doi:10.3390/cancers11050619 · Cited by 77
“As cancer cells exhibit metabolic plasticity [110,111], therapies targeting metabolism-modulating pathways will likely need to target parallel mechanisms fulfilling bioenergetic needs, or to combine metabolic inhibitors with therapeutic interventions that suppress cancer cell plasticity and thus the capacity for metab…”
Background
Metadata
- Authors
- Hulea, L., Gravel, S.-P., Morita, M., Cargnello, M., Uchenunu, O., Im, Y. K., Lehuédé, C., Ma, E. H., Leibovitch, M., McLaughlan, S., Blouin, M.-J., Parisotto, M., Papavasiliou, V., Lavoie, C., Larsson, O., Ohh, M., Ferreira, T., Greenwood, C., Bridon, G., Avizonis, D., Ferbeyre, G., Siegel, P., Jones, R. G., Muller, W., Ursini-Siegel, J., St-Pierre, J., Pollak, M., & Topisirovic, I.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 28
- Issue
- 6
- Pages
- 817-832.e8
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2891587993
- Cited by
- 91
- References
- 47
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.